Q4 2026 Zydus Lifesciences Ltd Earnings Call Transcript
Key Points
- Zydus Lifesciences Ltd (BOM:532321) reported strong double-digit growth for fiscal 2026, surpassing expectations.
- The company achieved its highest-ever operating profit and margins, with an EBITDA margin of 31.2%, up 80 basis points from the previous year.
- The U.S. formulations business experienced growth due to strong ForEx tailwinds, volume expansion, new launches, and sustained traction in the specialty portfolio.
- The branded formulations business in India outpaced the market with robust growth, driven by new product introductions and strong performance in key therapies.
- Zydus expanded its international presence by acquiring UK-based Comfort Click Limited, enhancing its footprint in the UK, EU, and US markets.
- Despite strong performance, the company faces increased competitive intensity in key products, particularly in the U.S. market.
- The medical devices business, while performing in line with expectations, will require time to deliver steady performance and profitability improvements.
- The company anticipates challenges related to competition and expenses associated with new product launches, which may impact margins.
- Zydus has a significant debt level, with net debt to EBITDA ratio at 0.5 times, and plans for further acquisitions could increase leverage.
- The company faces uncertainties in the geopolitical environment, which could impact supply chain stability and cost structures.
After management's opening remarks should you need any tap on the screen while asking questions request you to please identify yourself and your company please note this conference is being recorded I now hand over the conference to Mr Ganesh Nayak direct you and over to you sir hello yes sir.
We couldn't hear the last part.
This conference is being recorded. I now hand over the conference to Mr. Ganesh Nair, Director at Zydus Life Sciences. Thank you, and over to you, sir.
Good evening, ladies and gentlemen. It's my pleasure to welcome you all to our post-results teleconference for the fourth quarter. And the financial year ended March 31, 2026. For today's call, we have with us Dr. Sharil Patel, Managing Director Mr. Tushar Shroff, CFO Mr. Arvind Bothra, Head of Investor Relations and Mr. Alok Garg from the Managing Director's office. To begin with, let me give you an overview of the performance for the year.
I'm happy to inform you that we have ended the fiscal 2026 on a
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
